Eyegate Pharma (EYEG) Announces Kenneth Gayron and Aron Shapiro to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors
April 1, 2021 6:55 AM EDTWALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (EyeGate or the Company), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Companys Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven members. Both Mr. Gayron and Mr. Shapiro bring a unique perspective, deep expertise and valuable insight to the Company.
We are very pleased to... More
